ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 258 entries already.
Manufacturing of COVID vaccines showed that large-scale production of lipid nanoparticles (LNPs) as a delivery vehicle for mRNA vaccines is already possible. As nanocarrier-based formulations became mainstream, however, insufficiencies in existing technologies for routine GMP manufacturing became apparent. LEON is committed to bridging these technology gaps through its unique FR-JET technology and innovative manufacturing equipment.
The Swedish start-up AAX Biotech welcomed Maria Lisa Knudsen as its new Managing Director at the end of September.
For 25 years now, BioM has been the network organisation of the biotechnology sector in Munich and Bavaria. To shape the future of biotechnology, BioM identifies relevant and sustainable local, regional and global trends and creates a unique ecosystem for innovation and growth.
Stock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such megatrend investments help – up to the moment when rising interest rates crash the party.
Stock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such megatrend investments help – up to the moment when rising interest rates crash the party.
Individually customised therapies for every patient this is the vision of the future which numerous companies, research institutions, and clusters focusing on precision medicine in Saxony are working along the entire value creation chain. They are primarily active in oncology and have gained national and international acclaim and renown both in highly specialised cancer diagnostics and innovative treatment methods.
Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
London-based Engitix Ltd has appointed a new Chief Scientific Officer (CSO). Christopher Stevenson, Ph.D. took over the position at the beginning of September.
Eva Schlintl joined the LISAvienna team at the beginning of September. Most recently, she managed the LISA Life Science Austria programme of Austria Wirtschaftsservice Gesellschaft mbH (aws).
NorthX Biologics AB has appointed Dr Janet Hoogstraate as its new Chief Executive Officer, effective at the end of August.